Publications

5808 Results

Phase II studies of two different schedules of dasatinib in bone-metastasis predominant metastatic breast cancer: SWOG S0622

Authors
A Schott;W Barlow;C Van Poznak;D Hayes;C Moinpour;D Lew;C Reynolds;P Dy;E Keller;J Keller;G Hortobagyi
Journal / Conference
Breast Cancer Research and Treatment Aug;159(1):87-95; 2016 Jul 30 [Epub ahead of print]
Year
2016
Research Committee(s)
Breast
PMID
PMID27475087
PMC
PMC5021222
Study Number(s)
S0622

Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib

Authors
LA Carey;DA Berry;CT Cirrincione;WT Barry;BN Pitcher;LN Harris;DW Ollila;IE Krop;NL Henry;DJ Weckstein;CK Anders;B Singh;KA Hoadley;M Iglesia;M Cheang;C Perou;E Winer;C Hudis
Journal / Conference
Journal of Clinical Oncology, Feb 20;34(6):542-549
Year
2016
Research Committee(s)
Breast
PMID
PMID26527775
PMC
PMC4980567

Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: results from ACOSOG Z1071 (Alliance)

Authors
BG Haffty;LM McCall;KV Ballman;S McLaughlin;R Jagsi;DW Ollila;KS Hunt;TA Buchholz
Journal / Conference
International Journal of Radiation Oncology, Biology & Physics, Mar 94(3):493-502
Year
2016
Research Committee(s)
Breast
PMID
PMID26867878
PMC
PMC4752720

Identifying severe adverse event clusters using the National Cancer Institute's Common Terminology Criteria for Adverse Events

Authors
X Zhong;E Lim;DL Hershman;CM Moinpour;JM Unger;SM Lee
Journal / Conference
Journal of Oncology Practice, Mar;12(3):245-246
Year
2016
Research Committee(s)
Genitourinary
PMID
PMID26907453
PMC
PMC5702793
Study Number(s)
S9916

Addressing skyrocketing cancer drug prices comes with tradeoffs: pick your poison. [Opinion]

Authors
S Ramsey;GH Lyman;R Bangs
Journal / Conference
JAMA Oncology, Apr 1;2(4):425-426; 2016 Feb 11 [Epub ahead of print]
Year
2016
Research Committee(s)
Cancer Care Delivery
PMID
PMID26868102
PMC
PMC n/a [opinion article]

Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future [Review]

Authors
AW Smith;NL Seibel;DR Lewis;KH Albritton;DF Blair;CD Blanke;A Bleyer;DR Freyer;AM Geiger;B Hayes-Lattin;JV Tricoli;LI Wagner;BJ Zebrack
Journal / Conference
Cancer Apr 1;122(7):988-999
Year
2016
Research Committee(s)
Cancer Care Delivery
PMID
PMID26849003
PMC
PMC n/a - review article

Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials

Authors
DL Hershman;C Till;JD Wright;D Awad;S Ramsey;W Barlow;L Minasian;J Unger
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 10001); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation
Year
2016
Research Committee(s)
Breast, Genitourinary, Gynecologic, Head and Neck, and Lung
Study Number(s)
S0003, S0007, S0009, S0012, S0022, S0023, S0027, S0028, S0029, S0032, S0102, S0219, S0221, S0329, S0421, S0536, S0819, S9712, S9900, S9902, S9912, S9914, S9916

Azacitidine with or without entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study

Authors
T Prebet;Z Sun;R Ketterling;A Zeidan;P Greenberg;J Herman;M Juckett;MR Smith;L Malick;E Paietta;M Czader;M Figueroa;J Gabrilove;H Erba;M Tallman;M Litzow;S Gore
Journal / Conference
British Journal of Haematology, Feb;172(3):384-391
Year
2016
Research Committee(s)
Leukemia
PMID
PMID26577691
PMC
PMC4794257
Study Number(s)
E1905

Determinants of early mortality among 37,568 patients with colon cancer who participated in 25 clinical trials from the Adjuvant Colon Cancer Endpoints Database

Authors
WY Cheung;LA Renfro;D Kerr;A de Gramont;LB Saltz;A Grothey;SR Alberts;T Andre;KA Guthrie;R LaBianca;G Francini;J-F Seitz;C O'Callaghan;C Twelves;E Van Cutsem;DG Haller;G Yothers;DJ Sargent
Journal / Conference
Journal of Clinical Oncology, Apr 10;34(11):1182-1189
Year
2016
Research Committee(s)
Gastrointestinal
PMID
PMID26858337
PMC
PMC4933130
Study Number(s)
SWOG-9415 (INT-0153) (CALGB-9498) (ECOG-S9415) (NCCTG-S9415)

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Authors
AM Lee;Q Shi Qian;SR Alberts;DJ Sargent;FA Sinicrope;JL Berenberg;A Grothey;B Polite;E Chan;S Gill;MS Kahlenberg;SG Nair;AF Shields;RM Goldberg;RB Diasio
Journal / Conference
Pharmacogenetics and Genomics, Mar;26(3):133-137
Year
2016
Research Committee(s)
Gastrointestinal
PMID
PMID26658227
PMC
PMC4738010
Study Number(s)
CTSU/N0147